Crinetics Launches Palsonfi with 50% QuickStart Patients, Maintains $1B Cash Runway
Crinetics defined normalization of urinary cortisol as the primary endpoint for its Palsonfi phase 2/3 study, enabling measurement of biochemical markers alongside clinical outcomes like glucose and blood pressure improvements. The company has 50% of patients on QuickStart, 200 Q4 enrollments and over $1 billion cash supporting operations into 2030.
1. Primary Endpoint Defined
Crinetics set normalization of urinary cortisol as the primary endpoint for its Palsonfi phase 2/3 study, allowing direct measurement of biochemical disease activity alongside clinical markers such as glucose levels and blood pressure improvements.
2. Palsonfi Launch Progress
The launch has 50% of patients enrolled via QuickStart programs and recorded 200 Q4 enrollment forms; about half of patients receive reimbursement initially while QuickStart participants undergo 15-day check-ins, and management expects a lumpy uptake curve.
3. Financial Stability
Crinetics maintains over $1 billion in cash equivalents and investments, providing a runway into 2030 and covering under $100,000 of zero-cost inventory product revenue expenses.
4. Market Access Dynamics
Payer coverage aligns with the Palsonfi label, prior authorizations proceed smoothly with rapid clinical reviews for any step edits, and prescribers report positive feedback on the therapy's fast onset of action.